Criteria to qualify for study: Drug used in study:
  • R/R AML or MDS

HR 61

A Phase 1 Study of SEA-CD70 as monotherapy or in combination, in AML or MDS

Learn about the phase 1 study of SEA-CD70
  • AML, MDS or ALAL

BMT 37

Phase 1 study if escalating single and multiple doses of Mana 312 (Multi Tumor Associated Antigen T-Cells) Administered to adult subjects with Acute Myeloid Leukemia in first remission after conventional chemotherapy

Learn about the phase 1 study of Mana 312
  • Receive at least 1 prior line of therapy for AML or MDS; ECOG <2

HR 63

A phase 1 study of NKX101, an activating chimeric receptor natural killer (ACR NK) cell therapy, in subjects with hematological malignancies or dysplasias.

Learn about the phase 1 study of NKX101